Cost of cancer care varies widely based on who pays the bill
the ONA take:
Cost disparities in chemotherapy drugs can be substantial, reveals a new study from the University of North Carolina and Chapel Hill.
Researchers found uninsured patients with cancer are asked to pay on average 2 times more than Medicare recipients would pay for the same drugs, and that difference can go as high as 43 times more. The uninsured even pay more than those with private insurance.
Cost of doctor visits for cancer patients was also reviewed, and the same discrepancy in costs was seen. For example, uninsured patients were billed $129 to $391, depending on the complexity of the visit; however, Medicare and private insurance paid $65 to $188 and $78 to $246, respectively, for the same visits.
Researchers report that patients with Medicare or private insurance are paying a discounted rate for their health care. Uninsured patients do not have the bargaining power, or may not try to negotiate price on their own.
Uninsured patients with cancer are asked to pay on average 2 times more than Medicare recipients would pay for the same drugs
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|